Emeryville, CA – According to filings with the U.S. Securities and Exchange Commission, Nutcracker Therapeutics is raising $60,036,840.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Igor Khandros played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nutcracker Therapeutics

Founded in 2018, Nutcracker Therapeutics is bringing the combined power of high-technology engineering and advanced biosynthesis to RNA therapeutics. We have engineered a push-button mRNA synthesis and formulation platform. Armed with this high-tech advantage, we will advance mRNA therapeutics into the clinic through strategic partnerships with clinical institutions and pharmaceutical/biotech companies. When approved, our GMP-in-the-box approach to manufacturing is expected to offer significant cost, cycle time, capacity, and point-of-care execution advantages over other manufacturing approaches. Supporting our initial focus on oncology, our platform will ultimately enable the production of complex multimodal therapeutics at point of care.

To learn more about Nutcracker Therapeutics, visit http://www.nutcrackerx.com/

Contact:
Igor Khandros, Chief Executive Officer
510-473-8478

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved